RADNOR, Pa. - Mineralys Therapeutics , Inc. (NASDAQ:MLYS), a biopharmaceutical company specializing in the development of treatments for cardiovascular and kidney diseases, has announced the ...

Elicio Therapeutics aims for breakthrough treatment with ELI-002 in pancreatic cancer. Find out why ELTX stock may benefit ...

European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company’s Fully Human Albumin Binding (FHAB®) ...

The white substance is called albumin, a protein that is found naturally in salmon. The moisture-rich protein starts as a ...

Statins, a class of cholesterol-lowering drugs, have no effect on kidney function, a research team led by the University of Iowa has found.

A University of Iowa research team has found that a class of cholesterol-lowering drugs have no effect on kidney function.

Sirolimus albumin-bound is under clinical development by Aadi Bioscience and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Renal Cell Carcinoma have a 29% ...

SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis®) with ...

Sometimes you may receive a combination of therapies, or something else entirely. Oncology (cancer) drugs include a range of therapies and medications, such as chemotherapy drugs, targeted ...

1 Department of Cardiology, Bishan Hospital, Chongqing University of Chinese Medicine, Chongqing, China 2 Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, ...

"The $7.3 billion is the difference between what they are reimbursing themselves and what it is estimated to cost them to acquire the drug," an FTC spokesperson told reporters in a press briefing ...

Attribution (BY): Credit must be given to the creator. The binding ability of human serum albumin (HSA) on active pharmaceutical ingredients (APIs) is one of the most important parameters in the early ...